Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
NCT ID: NCT05926505
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
182 participants
INTERVENTIONAL
2023-09-06
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Giant Cell Arteritis and Anakinra Trial
NCT02902731
Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist
NCT04594356
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
NCT05911009
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
NCT06983821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The role of immune dysregulation in PACS is indirectly supported from the findings of the SAVE-MORE randomized clinical trial, in which patients with moderate and severe COVID-19, were 1:2 randomized to treatment with placebo or anakinra once daily for 10 days. The primary endpoint was the distribution of the frequencies of patients in the 11 points of the WHO clinical progression scale (CPS) by day 28. Patients' follow-up until day 90 showed significant reduction of the incidence of PACS; this was 24.4% among placebo-treated patients and 15.7% among patients treated with anakinra.
After the end of the SAVE-MORE trial, the understanding of the immune activation of PACS and the development of tools for the evaluation of patients have become the main aims of the Hellenic Institute for the study of sepsis (HISS) group. More precisely, patients with medical history of COVID-19 pneumonia during three separate time periods and matched comparators for age, sex, comorbidities, and state of vaccination were followed up and evaluated for PACS. Main findings can be summarized as follows:
1. For at least one year after acute COVID-19 there is considerable immune dysregulation involving both the innate and the adaptive responses.
2. Patients with PACS may be classified into four main phenotype clusters: fatigue involving 70.8%, respiratory cluster involving 33.2%, systemic symptoms involving 17.7% and other symptoms involving 26.1%.
3. The risk for progression into PACS was significantly lower among patients treated with anakinra in the acute stage (odds ratio 0.59, p: 0.017) showing a role of IL-1 for the progression into PACS.
4. Patients with fatigue bring distinct immunotype compared to the respiratory cluster.
5. IP-10 (interferon-gamma-induced protein-10) at levels more than 250 pg/ml has sensitivity 99.3%, specificity 90.9%, positive predictive value (PPV) 97.9% and negative predictive value (NPV) 97.6% for the diagnosis of the post acute COVID immune dysregulation.
PRECISION is a proof-of-concept, randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of anakinra in patients with PACS in improving the clinical and immunological state over 4 to 8 weeks as measured by a composite endpoint, namely, the "Score of PACS progression reversal".
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo is injected subcutaneously once daily for 4 weeks.
Placebo
Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
Anakinra
Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks.
Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female gender
3. In the case of women of childbearing age and men, an adequate method of contraception should be used during the study. Contraception should be maintained for at least a period of 3 months after the discontinuation of treatment. As an adequate method of contraception, it is suggested: -male or female condom with or without spermicide -contraceptive cap, a diaphragm or contraceptive sponge with a spermicide Prior to admission to the study, a pregnancy test will be performed to exclude pregnancy to women of childbearing age.
4. Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation in the Member State where the trial is planned.
5. History of confirmed COVID-19 infection the last 90 days or more
6. Symptoms compatible with PACS (defined as at least one positive answer to the questionnaire for restriction of daily activities) lasting for more than 2 months
7. Serum levels of IP-10 more than 250 pg/ml
8. Presence of ONE of the following two clinical conditions: Condition 1: Impaired Lung Function tests (defined as: DLCOcor \<76% AND TLC and/or FVC lower than 80% of predicted) Condition 2: At least a total radiology score in HRCT more than 20 OR walking of a distance less than 500m in the 6-minute walk test
If patients meet the criteria for both Conditions 1 and 2, they will be considered for randomization and evaluation for the primary endpoint as in Condition 1.
Exclusion Criteria
2. Denial for written informed consent
3. Any stage IV malignancy
4. Any primary immunodeficiency
5. Less than 1,500 neutrophils/mm3
6. Known hypersensitivity to anakinra
7. Known lung fibrosis prior to COVID-19
8. Medical history of pulmonary hypertension or chronic heart failure
9. Known chronic obstructive pulmonary disease GOLD stage 3 or 4 prior to COVID-19
10. Known active tuberculosis (under treatment) or latent tuberculosis (by positive tuberculin test)
11. Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days.
12. Any anti-cytokine biological treatment the last one month
13. Severe hepatic failure defined as Child-Pugh stage of 3
14. End-stage renal failure necessitating hemofiltration or peritoneal hemodialysis
15. Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study
16. Participation in any other interventional trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hellenic Institute for the Study of Sepsis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Evangelos Giamarelos-Bourboulis, MD,PhD
Role: STUDY_CHAIR
Hellenic Institute for the Study of Sepsis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Out-patient long-COVID department, Jena University Hospital
Jena, , Germany
Out-patient long-COVID department, Patras University General Hospital
Pátrai, Achaia, Greece
Out-patient long-COVID department III, Evangelismos Athens General Hospital
Athens, Attica, Greece
Out-patient long-COVID department I, Sotiria Athens Hospital of Chest Diseases
Athens, Attica, Greece
Out-patient long-COVID department II, Sotiria Athens Hospital of Chest Diseases
Athens, Attica, Greece
Out-patient long-COVID department IV, Sotiria Athens Hospital of Chest Diseases
Athens, Attica, Greece
Out-patient long-COVID department, Laiko General Hospital
Athens, Attica, Greece
2nd Department of Propedeutic Medicine, ATTIKON University General Hospital
Chaïdári, Attica, Greece
4th Department of Internal Medicine, ATTIKON University General Hospital
Chaïdári, Attica, Greece
Out-patient long-COVID department, Ioannina University General Hospital
Ioannina, Ioannina, Greece
Out-patient long-COVID department, Tzaneion Piraeus General Hospital
Piraeus, Piraeus, Greece
Out-patient long-COVID department, Alexandroupolis University General Hospital
Alexandroupoli, , Greece
Out-patient long-COVID department X, Sotiria Athens Hospital of Chest Diseases
Athens, , Greece
Out-patient long-COVID department, University Hospital of Larissa
Larissa, , Greece
Out-patient long-COVID department II, Thriasio General Hospital of Elefsina
Magoula, , Greece
Out-patient long-COVID department I, Thriasio General Hospital of Elefsina
Magoula, , Greece
Out-patient long-COVID department, AHEPA Hospital of Thessaloniki
Thessaloniki, , Greece
Infectious Diseases Clinic, Ospedale Policlinico San Martino IRCCS and Department of Health Sciences, University of Genova, Genoa, Italy
Genova, , Italy
Department of Internal Medicine, Hospital of Jesolo, Italy
Jesolo, , Italy
Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele & Vita-Salute San Raffaele University, Milan, Italy
Milan, , Italy
Infectious Diseases Clinic, University of Modena, Italy
Modena, , Italy
Dipartimento Scienze di Laboratorio e Infettivologiche - Fondazione Policlinico Gemelli IRCCS, Roma Italy
Rome, , Italy
ID Respiratory Unit, Spallanzani Institute of Rome, Italy
Rome, , Italy
Department of Pulmonary Medicine, Barcelona University Hospital
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
P. Reuken
Role: primary
M. Bassetti, MD, PhD
Role: primary
Francesco Saverio-Serino, MD
Role: primary
L. Dagna
Role: primary
Giovanni Guaraldi, MD, PhD
Role: primary
M. Fantoni
Role: primary
Fabrizio Palmieri, MD
Role: primary
A. Torres
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-000102-25
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
PRECISION
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.